GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (NAS:PHAR) » Definitions » Debt-to-Revenue

PHAR (Pharming Group) Debt-to-Revenue : 0.42 (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Pharming Group Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Pharming Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $7.2 Mil. Pharming Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $119.9 Mil. Pharming Group's annualized Revenue for the quarter that ended in Sep. 2024 was $299.4 Mil. Pharming Group's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 was 0.42.


Pharming Group Debt-to-Revenue Historical Data

The historical data trend for Pharming Group's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharming Group Debt-to-Revenue Chart

Pharming Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.31 0.76 0.81 0.81 0.70

Pharming Group Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.62 0.53 0.75 0.41 0.42

Competitive Comparison of Pharming Group's Debt-to-Revenue

For the Biotechnology subindustry, Pharming Group's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharming Group's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharming Group's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Pharming Group's Debt-to-Revenue falls into.



Pharming Group Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Pharming Group's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(5.44 + 166.105) / 245.316
=0.70

Pharming Group's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(7.201 + 119.883) / 299.396
=0.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2024) Revenue data.


Pharming Group Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Pharming Group's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharming Group Business Description

Traded in Other Exchanges
Address
Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.